Navigation Links
BioMS Medical warrant extension
Date:3/2/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, March 2 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that effective on March 16, 2009 the exercise term of 11,500,000 share purchase warrants, each of which entitles the holder to purchase one Class A common share at a price of $5.00 per share, will be extended from March 23, 2009 to December 31, 2009.

On March 18, 2008, BioMS Medical's Board of Directors passed a resolution to extend 10,514,000 of the warrants, the portion held by warrant holders who are at arm's length to the Company. At the Company's annual general meeting held on May 9, 2008, the shareholders holding a majority of the Class A common shares, excluding the votes attached to Class A common shares held by insiders whose warrants were being amended, approved the extension for the remaining 986,000 warrants held by insiders.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Freeslate, ... solutions, today announced that Lupin Limited, one of India’s ... CM Protégé PharmD System for high throughput ... India, is focused on a wide range of quality, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo announced ... from the National Institutes of Health (NIH) to help ... effective treatments to patients on a faster timeline. Organovo ... Sciences (NCATS) and the National Eye Institute (NEI) to ...
(Date:1/14/2014)... OTTAWA, Ontario , Jan. 14, 2014   Kinaxis ®, ... ( SCM ) and sales and operations planning ( S&OP ... the Biomanufacturing Summit , which will be held at ...  At the conference, join Kinaxis customer Elisabeth Kaszas , ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Tumors Associated ... with HER2-Positive Breast Cancer, SAN ANTONIO, Texas, Dec. ... a Phase II study on its,first-in-class, oral small molecule HER2 ... the combination of,TYKERB plus capecitabine (Xeloda(R)) showed a reduction in ...
... - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) and ... pharmaceutical and medical devices company, today,announced the ... System,in Germany. Celacade, a first-in-class therapy, is ... targets the destructive chronic,inflammation underlying the development ...
... Mednet, SWOG Will Enhance Quality and Speed Image Transfer at ... Cost While Ensuring 21 CFR Part 11 ... largest,diagnostic imaging network, today announced it has been selected by,Southwest ... trials cooperative groups in the United States, to provide a,secure, ...
Cached Biology Technology:GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 2GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 3GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 4GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 5GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 6Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 2Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 3Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 4Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 5AG Mednet to Provide Image Network for Southwest Oncology Group 2
(Date:4/21/2014)... lower cholesterol can reduce heart attack and stroke risk, ... save the vision of diabetics, scientists say. , In ... of niacin to decrease bad cholesterol levels and raise ... for these patients, said Dr. Pamela Martin, biochemist at ... , Martin is Principal Investigator on a new ...
(Date:4/20/2014)... 20, 2014) A team of researchers from ... College, and Brandeis University has devised a wholly ... involving the so-called retromer protein complex. Retromer plays ... protein (APP) away from a region of the ... toxic byproduct amyloid-beta, which is thought to contribute ...
(Date:4/20/2014)... Although doctors have long known that people with Down ... leukemia (ALL) during childhood, they haven,t been able to ... Institute investigators has uncovered a connection between the two ... the journal Nature Genetics , the researchers track ... abnormality in Down syndrome to the cellular havoc that ...
Breaking Biology News(10 mins):Scientists target receptor to treat diabetic retinopathy 2Scientists target receptor to treat diabetic retinopathy 3'Chaperone' compounds offer new approach to Alzheimer's treatment 2'Chaperone' compounds offer new approach to Alzheimer's treatment 3Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3
... La Jolla, CA - Salk Institute professor Terrence J. ... the neural networks revolution in computing in the 1980s, ... of Sciences. The Academy made the announcement today during ... the Academy recognizes distinguished and continuing achievements in original ...
... CARSON CITY, Nev. , April 27 State of ... by participating in The Prevention Plan™, a U.S. Preventive Medicine® program designed to ... before they progress. The program is projected to save Nevada ... , , ...
... , ATLANTA , April 27   Georgia Power received approval April 20 ... more solar options. , , , ... , , ... to include the following: , , , ...
Cached Biology News:Salk scientist Terrence Sejnowski elected to National Academy of Sciences 2U.S. Preventive Medicine Helps Participants of the State of Nevada Public Employees' Benefits Program (PEBP) Become Healthier 2U.S. Preventive Medicine Helps Participants of the State of Nevada Public Employees' Benefits Program (PEBP) Become Healthier 3Georgia Power's Green Energy Program Redesigned to Include More Solar Power 2
... advanced protein cross-linking techniques are defined by ... Shan S. Wong. This valuable hardcover guide ... and current application references. More than 300 ... cross-linking and conjugate preparation from selection ...
... The proteomic service includes protein separation ... using the PDQuest software package from ... mass spectrometry. In order to meet ... preparation, data analysis and format of ...
... provides reagents for immune complex disruption (ICD) ... samples using a combination of low pH ... and transferred to microplate wells which are ... antibody to HIV-1 p24. The immobilized monoclonal ...
... endotoxin-free plasmid DNA preparations are prepared ... quantities from 1mg to multi-gram scales. ... customer needs, and glycerol stocks are ... Transformation, clonal selection (Clonal selection includes ...
Biology Products: